Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 8 (March 10), 2006: pp. 1253-1265
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.04.5302

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Reardon, D. A.
Right arrow Articles by Bigner, D. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reardon, D. A.
Right arrow Articles by Bigner, D. D.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

REVIEW ARTICLE

Recent Advances in the Treatment of Malignant Astrocytoma

David A. Reardon, Jeremy N. Rich, Henry S. Friedman, Darell D. Bigner

From the Departments of Surgery, Pediatrics, and Pathology, Duke University Medical Center, Durham, NC

Address reprint requests to David A. Reardon, the Preston Robert Tisch Brain Tumor Center at Duke University, Duke University Medical Center, Box 3624, Durham, NC 27710; e-mail: reard003{at}mc.duke.edu

Malignant gliomas, including the most common subtype, glioblastoma multiforme (GBM), are among the most devastating of neoplasms. Their aggressive infiltration in the CNS typically produces progressive and profound disability—ultimately leading to death in nearly all cases. Improvement in outcome has been elusive despite decades of intensive clinical and laboratory research. Surgery and radiotherapy, the traditional cornerstones of therapy, provide palliative benefit, while the value of chemotherapy has been marginal and controversial. Limited delivery and tumor heterogeneity are two fundamental factors that have critically hindered therapeutic progress. A novel chemoradiotherapy approach, consisting of temozolomide administered concurrently during radiotherapy followed by adjuvant systemic temozolomide, has recently demonstrated a meaningful, albeit modest, improvement in overall survival for newly diagnosed GBM patients. As cell-signaling alterations linked to the development and progression of gliomas are being increasingly elucidated, targeted therapies have rapidly entered preclinical and clinical evaluation. Responses to therapies that function via DNA damage have been associated with specific mediators of resistance that may also be subject to targeted therapies. Other approaches include novel locoregional delivery techniques to overcome barriers of delivery. The simultaneous development of multiple advanced therapies based on specific tumor biology may finally offer glioma patients improved survival.

Supported by National Institutes of Health Grants No. NS20023, CA11898, and MO1 RR 30, General Clinical Research Centers Program, National Center for Research Resources, National Cancer Institute Grant No. SPORE 1 P20 CA096890, and additional funding support from the Pediatric Brain Tumor Foundation of the United States and the Accelerate Brain Cancer Cure (ABC 2) Foundation.

Authors' disclosures of potential conflicts of interest and author contributors are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Neuro OncologyHome page
S. Spiegl-Kreinecker, C. Pirker, M. Filipits, D. Lotsch, J. Buchroithner, J. Pichler, R. Silye, S. Weis, M. Micksche, J. Fischer, et al.
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients
Neuro Oncology, October 15, 2009; (2009) nop003v1.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Paternot and P. P. Roger
Combined Inhibition of MEK and Mammalian Target of Rapamycin Abolishes Phosphorylation of Cyclin-Dependent Kinase 4 in Glioblastoma Cell Lines and Prevents Their Proliferation
Cancer Res., June 1, 2009; 69(11): 4577 - 4581.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
C. Mikelis, E. Sfaelou, M. Koutsioumpa, N. Kieffer, and E. Papadimitriou
Integrin {alpha}{nu}{beta}3 is a pleiotrophin receptor required for pleiotrophin-induced endothelial cell migration through receptor protein tyrosine phosphatase {beta}/{zeta}
FASEB J, May 1, 2009; 23(5): 1459 - 1469.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
H. Zheng, H. Ying, H. Yan, A.C. Kimmelman, D.J. Hiller, A.-J. Chen, S.R. Perry, G. Tonon, G.C. Chu, Z. Ding, et al.
Pten and p53 Converge on c-Myc to Control Differentiation, Self-renewal, and Transformation of Normal and Neoplastic Stem Cells in Glioblastoma
Cold Spring Harb Symp Quant Biol, January 15, 2009; (2009) sqb.2008.73.047v1.
[Abstract] [PDF]


Home page
Neuro Oncol DukeHome page
Q. Zhou and J. M. Gallo
Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model
Neuro-oncol, January 1, 2009; 11(3): 301 - 310.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H.-W. Lo, X. Cao, H. Zhu, and F. Ali-Osman
Constitutively Activated STAT3 Frequently Coexpresses with Epidermal Growth Factor Receptor in High-Grade Gliomas and Targeting STAT3 Sensitizes Them to Iressa and Alkylators
Clin. Cancer Res., October 1, 2008; 14(19): 6042 - 6054.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
L. W Buie and J. Valgus
Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme
Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. S. Ziegler, A. L. Kung, and M. W. Kieran
Anti-Apoptosis Mechanisms in Malignant Gliomas
J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Claes, P. Wesseling, J. Jeuken, C. Maass, A. Heerschap, and W. P.J. Leenders
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization
Mol. Cancer Ther., January 1, 2008; 7(1): 71 - 78.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Aoki, T. Yokoyama, K. Fujiwara, A. M. Tari, R. Sawaya, D. Suki, K. R. Hess, K. D. Aldape, S. Kondo, R. Kumar, et al.
Phosphorylated Pak1 Level in the Cytoplasm Correlates with Shorter Survival Time in Patients with Glioblastoma
Clin. Cancer Res., November 15, 2007; 13(22): 6603 - 6609.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. M. Alonso, M. Cascallo, C. Gomez-Manzano, H. Jiang, B. N. Bekele, A. Perez-Gimenez, F. F. Lang, Y. Piao, R. Alemany, and J. Fueyo
ICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo
Cancer Res., September 1, 2007; 67(17): 8255 - 8263.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. B. Axelsen, J. Lotem, L. Sachs, and E. Domany
Genes overexpressed in different human solid cancers exhibit different tissue-specific expression profiles
PNAS, August 7, 2007; 104(32): 13122 - 13127.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
A. Iwamaru, E. Iwado, S. Kondo, R. A. Newman, B. Vera, A. D. Rodriguez, and Y. Kondo
Eupalmerin acetate, a novel anticancer agent from Caribbean gorgonian octocorals, induces apoptosis in malignant glioma cells via the c-Jun NH2-terminal kinase pathway
Mol. Cancer Ther., January 1, 2007; 6(1): 184 - 192.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Goldberg and Y. Kloog
A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinase-Dependent Glioblastoma Cell Migration
Cancer Res., December 15, 2006; 66(24): 11709 - 11717.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. Redjal, J. A. Chan, R. A. Segal, and A. L. Kung
CXCR4 Inhibition Synergizes with Cytotoxic Chemotherapy in Gliomas.
Clin. Cancer Res., November 15, 2006; 12(22): 6765 - 6771.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Pellegatta, P. L. Poliani, D. Corno, F. Menghi, F. Ghielmetti, B. Suarez-Merino, V. Caldera, S. Nava, M. Ravanini, F. Facchetti, et al.
Neurospheres Enriched in Cancer Stem-Like Cells Are Highly Effective in Eliciting a Dendritic Cell-Mediated Immune Response against Malignant Gliomas
Cancer Res., November 1, 2006; 66(21): 10247 - 10252.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C. Grommes, G. E. Landreth, M. Sastre, M. Beck, D. L. Feinstein, A. H. Jacobs, U. Schlegel, and M. T. Heneka
Inhibition of in Vivo Glioma Growth and Invasion by Peroxisome Proliferator-Activated Receptor {gamma} Agonist Treatment
Mol. Pharmacol., November 1, 2006; 70(5): 1524 - 1533.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
J. A. McCubrey, M. M. LaHair, and R. A. Franklin
OSU-03012 in the Treatment of Glioblastoma
Mol. Pharmacol., August 1, 2006; 70(2): 437 - 439.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. S. Lawrence, J. C. Buckner, and F. F. Lang
CNS Malignancies: At Last, Real Progress
J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online